| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0025-6196(12)64916-7 |
| P698 | PubMed publication ID | 3172850 |
| P2093 | author name string | P C de Groen | |
| P2860 | cites work | Liver transplantation with use of cyclosporin a and prednisone | Q24645567 |
| Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid | Q28269728 | ||
| Cerebrotendinous xanthomatosis: a defect in mitochondrial 26-hydroxylation required for normal biosynthesis of cholic acid | Q28367184 | ||
| A receptor-mediated pathway for cholesterol homeostasis | Q29616158 | ||
| Cyclophilin: a specific cytosolic binding protein for cyclosporin A | Q29620548 | ||
| Effect of Cyclosporin A on prostacyclin synthesis by vascular tissue | Q33477459 | ||
| Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: a study using quail--chick transplantation chimeras | Q34057185 | ||
| Overexpression of low density lipoprotein (LDL) receptor eliminates LDL from plasma in transgenic mice | Q34175241 | ||
| Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia | Q34248358 | ||
| Heart-liver transplantation in a patient with familial hypercholesterolaemia | Q34291627 | ||
| mRNA for low density lipoprotein receptor in brain and spinal cord of immature and mature rabbits | Q34344169 | ||
| Cyclosporin A in patients receiving renal allografts from cadaver donors | Q34347891 | ||
| Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system | Q34559847 | ||
| Expression of apolipoprotein E during nerve degeneration and regeneration | Q35591346 | ||
| Nerve injury stimulates the secretion of apolipoprotein E by nonneuronal cells | Q35591372 | ||
| Targeted killing of cultured cells by receptor-dependent photosensitization | Q36369270 | ||
| Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets | Q37672903 | ||
| Cyclosporin A for the treatment of graft-versus-host disease in man | Q39521114 | ||
| Cerebrotendinous xanthomatosis: a review of biochemical findings of the patient population in The Netherlands | Q39602150 | ||
| Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia | Q40135695 | ||
| The Influence of Human Plasma Lipoproteins and Fatty Acids in Immunological Reactions | Q40140226 | ||
| Identification of a lymphocyte surface receptor for low density lipoprotein inhibitor, an immunoregulatory species of normal human serum low density lipoprotein | Q40152561 | ||
| Low Density Lipoprotein Receptors in Bovine Adrenal Cortex. II. Low Density Lipoprotein Binding to Membranes Prepared from Fresh Tissue* | Q40223308 | ||
| Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid | Q42208051 | ||
| Cyclosporin A inhibits PGE2 release from vascular smooth muscle cells | Q42512172 | ||
| Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity | Q43792789 | ||
| A new method for measuring the free fraction of cyclosporin in plasma by equilibrium dialysis | Q43907983 | ||
| The immunosuppressive activities of different cyclosporins are correlated to inhibition of the early membrane phospholipid metabolism in activated lymphocytes | Q44805770 | ||
| Psychiatric disorders in patients with cerebrotendinous xanthomatosis | Q48104322 | ||
| Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol | Q48201659 | ||
| Magnetic resonance imaging in cerebrotendinous xanthomatosis | Q48391413 | ||
| Restrictive transport of a lipid-soluble peptide (cyclosporin) through the blood-brain barrier | Q48431164 | ||
| Disturbance of blood-brain barrier after bone-marrow transplantation | Q48462853 | ||
| Severe central-nervous-system toxicity associated with cyclosporin | Q48534631 | ||
| Experimental Studies of Blood Brain Barrier Permeability in Acute Hepatic Failure | Q48678382 | ||
| EEG in cerebrotendinous xanthomatosis (CTX). | Q48957920 | ||
| Interaction of cyclosporin A with human lipoproteins. | Q51633215 | ||
| Astrocytes induce blood–brain barrier properties in endothelial cells | Q57318253 | ||
| NEUROLOGICAL COMPLICATIONS FOLLOWING LIVER TRANSPLANTATION | Q61797092 | ||
| Cyclosporine-associated central nervous system toxicity | Q68278231 | ||
| Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins | Q68921833 | ||
| Cerebral blindness and encephalopathy with cyclosporin A toxicity | Q69034294 | ||
| Porphyrin-lipoprotein association as a factor in porphyrin localization | Q69686928 | ||
| Biochemical mechanisms underlying cyclosporine-induced nephrotoxicity. Effect of concomitant administration of prednisolone | Q69806143 | ||
| High cyclosporin levels after bone marrow transplantation associated with hypertriglyceridaemia | Q69887517 | ||
| Cyclosporin: measurement of fraction unbound in plasma | Q69906625 | ||
| Long-term effects of cyclosporin A on cultured mouse pancreatic islets | Q70381435 | ||
| Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2 | Q70554049 | ||
| Computed tomography in cerebrotendinous xanthomatosis | Q70670541 | ||
| Antischistosomal effects of cyclosporin A | Q70930242 | ||
| Inhibition of T-cell activity by cyclosporin A | Q71612132 | ||
| Selective delivery of cytotoxic compounds to cells by the LDL pathway | Q72386576 | ||
| Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood | Q72541756 | ||
| Cyclosporin-A deposits in renal allografts | Q72556296 | ||
| HLA-DR antigens render interleukin-2-producer T lymphocytes sensitive to interleukin-1 | Q72658159 | ||
| P433 | issue | 10 | |
| P921 | main subject | cyclosporine | Q367700 |
| P304 | page(s) | 1012-1021 | |
| P577 | publication date | 1988-10-01 | |
| P1433 | published in | Mayo Clin Proc | Q6538184 |
| P1476 | title | Cyclosporine, low-density lipoprotein, and cholesterol | |
| P478 | volume | 63 |
| Q35833075 | Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. |
| Q37050333 | Applications of LDL-apheresis in nephrology |
| Q50182160 | Bile acid metabolism and biliary secretion in patients receiving orthotopic liver transplants: differing effects of cyclosporine and FK 506. |
| Q48186516 | Brain perfusion imaging in asymptomatic patients receiving cyclosporin |
| Q34976738 | Cardiovascular toxicities of immunosuppressive agents |
| Q35006255 | Cholesteryl ester transfer protein facilitates the movement of water-insoluble drugs between lipoproteins: a novel biological function for a well-characterized lipid transfer protein |
| Q41201529 | Clinically significant drug interactions with cyclosporin. An update |
| Q44127332 | Cyclosporin A pharmacokinetics in a patient with psoriasis and obesity, presenting with high levels of low-density [correction for destiny] lipoprotein |
| Q40918376 | Cyclosporin clinical pharmacokinetics |
| Q40699693 | Cyclosporine A-induced toxicity in two renal cell culture models (LLC-PK1 and MDCK). |
| Q67766993 | Decreased postheparin lipolytic activity in renal transplant recipients with cyclosporin A |
| Q34749073 | Distribution of cyclosporin in organ transplant recipients |
| Q36348396 | Drug therapy for inflammatory bowel disease: Part II. |
| Q77452765 | Drugs causing dyslipoproteinemia |
| Q43963075 | Dyslipemia and long-term immunosuppression |
| Q26851294 | Dyslipidemia and its therapeutic challenges in renal transplantation |
| Q26771723 | Dyslipidemia in Dermatological Disorders |
| Q72809759 | Effect of early hyperlipidemia on graft and patient survival in cyclosporine-treated renal transplant patients |
| Q73849614 | Effects of low and high density lipoproteins on renal cyclosporine A and cyclosporine G disposition in the isolated perfused rat kidney |
| Q71860750 | Efficacy and Pharmacokinetics of Simvastatin in Heart Transplant Recipients |
| Q44515223 | High-fat meals increase the clearance of cyclosporine |
| Q28261086 | Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery |
| Q73140016 | Incidence of cardiovascular risk factors and complications after kidney transplantation |
| Q43440566 | Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia |
| Q58561315 | Lipid management in patients with chronic kidney disease |
| Q74027154 | Lipoprotein changes in children after liver transplantation: mild hypertriglyceridemia and a decrease in HDL3/HDL2 ratio |
| Q47940037 | Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients |
| Q35771484 | Management of hyperlipidaemia associated with heart transplantation |
| Q57976278 | Mechanisms of calcineurin inhibitor-induced neurotoxicity |
| Q34170300 | Modern immunosuppression |
| Q39312540 | Negative Cardiovascular Consequences of Small Molecule Immunosuppressants. |
| Q35695021 | Neuropathologic findings after liver transplantation |
| Q37183438 | Pioglitazone abrogates cyclosporine-evoked hypertension via rectifying abnormalities in vascular endothelial function. |
| Q46483685 | Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis |
| Q28076119 | Post-transplant dyslipidemia: Mechanisms, diagnosis and management |
| Q40747345 | Posttransplant hyperlipidemia: the treatment dilemma |
| Q40714436 | Prevention and management of the adverse effects associated with immunosuppressive therapy |
| Q72326326 | Prompt remission of post-renal transplant nephrotic syndrome with high-dose cyclosporine |
| Q35088663 | Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: studies with cyclosporine A. |
| Q42201207 | Selective inhibition of mitochondrial 27-hydroxylation of bile acid intermediates and 25-hydroxylation of vitamin D3 by cyclosporin A. |
| Q67933126 | Synthesis of a Fluorescent Derivative of Cyclosporin A for High-Performance Liquid Chromatography Analysis |
| Q90136673 | The Many Faces of Calcineurin Inhibitor Toxicity-What the FK? |
| Q51610594 | The adverse impact of cyclosporine on serum lipids in renal transplant recipients. |
| Q43979099 | The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study |
| Q42963033 | Unusual cyclosporin related neurological complications in recipients of liver transplants |
Search more.